- Report
- January 2026
- 194 Pages
Global
From €3220EUR$3,545USD£2,780GBP
€3578EUR$3,939USD£3,089GBP
- Report
- June 2026
- 196 Pages
Global
From €3220EUR$3,545USD£2,780GBP
€3578EUR$3,939USD£3,089GBP
- Report
- June 2026
- 197 Pages
Global
From €3220EUR$3,545USD£2,780GBP
€3578EUR$3,939USD£3,089GBP
- Report
- January 2026
- 195 Pages
Global
From €3220EUR$3,545USD£2,780GBP
€3578EUR$3,939USD£3,089GBP
- Report
- January 2026
- 195 Pages
Global
From €3220EUR$3,545USD£2,780GBP
€3578EUR$3,939USD£3,089GBP
- Report
- August 2025
- 196 Pages
Global
From €3220EUR$3,545USD£2,780GBP
€3578EUR$3,939USD£3,089GBP
- Report
- August 2025
- 184 Pages
Global
From €3220EUR$3,545USD£2,780GBP
€3578EUR$3,939USD£3,089GBP
- Report
- February 2026
- 250 Pages
Global
From €4079EUR$4,490USD£3,521GBP
- Report
- February 2026
- 250 Pages
Global
From €4079EUR$4,490USD£3,521GBP
- Report
- February 2026
- 250 Pages
Global
From €4079EUR$4,490USD£3,521GBP
- Report
- February 2026
- 250 Pages
Global
From €4079EUR$4,490USD£3,521GBP
- Report
- February 2026
- 250 Pages
Global
From €4079EUR$4,490USD£3,521GBP
- Report
- February 2026
- 250 Pages
Global
From €4079EUR$4,490USD£3,521GBP
- Report
- February 2026
- 250 Pages
Global
From €4079EUR$4,490USD£3,521GBP
- Report
- May 2026
- 177 Pages
Global
From €4088EUR$4,500USD£3,529GBP
- Report
- January 2026
- 182 Pages
Global
From €4088EUR$4,500USD£3,529GBP
- Report
- April 2026
- 356 Pages
Global
From €7258EUR$7,990USD£6,266GBP
- Report
- July 2025
- 350 Pages
Global
From €4496EUR$4,949USD£3,881GBP
- Report
- April 2026
- 135 Pages
Global
From €3633EUR$3,999USD£3,136GBP
- Report
- March 2026
- 146 Pages
Global
From €3633EUR$3,999USD£3,136GBP

Ezetimibe is a cholesterol-lowering drug used to treat high cholesterol and other lipid disorders. It works by reducing the absorption of cholesterol from the intestine, thereby reducing the amount of cholesterol in the blood. Ezetimibe is often used in combination with statins, another type of cholesterol-lowering drug, to further reduce cholesterol levels. It is also used to reduce the risk of cardiovascular events, such as heart attack and stroke, in people with existing cardiovascular disease.
Ezetimibe is a relatively new drug, having been approved by the US Food and Drug Administration in 2002. It is now widely used in the treatment of high cholesterol and other lipid disorders, and is increasingly being used in combination with statins to further reduce cholesterol levels.
Ezetimibe is marketed by several pharmaceutical companies, including Merck, Pfizer, Sanofi, and Daiichi Sankyo. It is also available in generic form from several generic drug manufacturers. Show Less Read more